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INTRODUCTION
The drug-susceptibility test (DST) is essential for detecting
drug-resistant tuberculosis (TB) and designing effective reg-
imens for treating individual patients. Although the clinical
accuracy of DST has been debated, it produces quite reliable
results for susceptibility to isoniazid, rifampicin, and strep-
tomycin (1). However, the proportional method using Lowen-
stein-Jensen media usually takes longer than four weeks to
execute (2, 3).
Although recent guidelines recommend that pyrazinamide
be withdrawn after two months of intensive treatment (4-6),
the long turnaround time of the DST based on conventional
Lowenstein-Jensen media could prolong the use of pyrazi-
namide because clinicians may wait for confirmation of drug
resistance before terminating treatment. 
However, there are no reports on the actual turnaround
times of DSTs for which solid media are used when TB pati-
ents are treated in outpatient clinics. The aim of this study
is to determine the interval between initiation of anti-TB
treatment and receipt of the results of solid-media DSTs for
patients with culture-positive pulmonary TB who were treat-
ed in an outpatient clinic.
MATERIALS AND METHODS
Subjects and follow-up
We prospectively enrolled patients for whom anti-TB med-
ication was started at Seoul National University Hospital, a
tertiary referral hospital, from September 2002 to December
2004. Patients who agreed to participate in the study were
followed up on a monthly basis, after their first revisit two
weeks from initiation of anti-TB treatment. Of these, only
patients with culture-confirmed TB were included in the
analysis. We excluded patients who missed a scheduled visit
and failed to present themselves at the clinic during the sub-
sequent fortnight or who were transferred out before the results
of their DSTs were received by their clinicians. However, pa-
tients who, for various reasons, visited the clinic before the
scheduled follow-up day were included in the analysis. Treat-
ment consisted of daily self-administered therapy. Direct ob-
servation of ingestion of anti-TB drugs is not included in the
national TB control policy of Korea (7). The protocol had been
approved by Seoul National University Hospital ethics review
committee and the written consents were obtained from all
participants.
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The Interval Between Initiation of Anti-tuberculosis Treatment in
Patients with Culture-positive Pulmonary Tuberculosis and Receipt of
Drug-susceptibility Test Results
Although mycobacterial culture and the subsequent drug-susceptibility test (DST)
for anti-tuberculosis (TB) drugs take several months to complete using solid media,
there are no reports on the turnaround times of these tests under clinical conditions.
The aim of this study was to determine the interval between initiation of anti-TB treat-
ment and receipt of DST requested at an outpatient clinic. We prospectively enrolled
patients with culture-positive pulmonary TB at Seoul National University Hospital
from September 2002 to December 2004. Patients were followed up monthly. My-
cobacterial cultures were done using Ogawa media at Seoul National University
Hospital. DST were performed at the Korean Institute of Tuberculosis. Of the 104
patients enrolled, 54 were male. The median age was 41 yr. The median interval
from initiation of anti-TB treatment to receipt of mycobacterial culture results by clini-
cians was 37 days (range, 0-89 days). The median interval from initiation of treat-
ment to confirmation of DST by requesting clinicians was 80.5 days (range, 28-145
days). Clinicians only received the results of DST more than two months after initi-
ation of treatment when they followed up patients monthly and mycobacterial culture
was performed using solid media. 
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Mycobacterial cultures and drug-susceptibility tests
Mycobacterial cultures were done in 3% Ogawa media at
Seoul National University Hospital. Experienced technicians
recorded the results of cultures every monday and designat-
ed negative if colonies were absent after nine weeks of incu-
bation. Colonies from positive cultures were sent on tues-
days for DSTs to the Korean Institute of Tuberculosis, the
supranational reference laboratory for mycobacterial culture
and DSTs. The transfer time from Seoul National University
Hospital to the Korean Institute of Tuberculosis was about
two hours. DSTs for anti-TB drugs were performed using
Lowenstein-Jensen media and the proportional method. 
Receipt of the results of DST
The results of DSTs were sent from the Korean Institute of
Tuberculosis to Seoul National University Hospital on tues-
days. Clinicians checked whether reports had been received
each time their patients visited the clinic. If a report was not
received by the time of the visit, the duty clinician contact-
ed the Korean Institute of Tuberculosis through telephone or
via their website, http://tb.knta.or.kr/, to confirm that the
results were unavailable.
RESULTS
Baseline characteristics of patients
Of the 167 patients who participated, 119 were diagnosed
with culture-positive pulmonary TB and were enrolled in
the study. Of the 119, 15 were excluded from the analysis
because they missed a scheduled visit and failed to present
themselves at the clinic during the subsequent fortnight or
were transferred out before their clinicians received the results
of their DSTs. Data from 104 patients were included in the
final analysis. Of the patients, 54 (55%) were male. The me-
dian age was 41 yr (range 17-85 yr). Forty-six patients (44%)
were diagnosed as having both smear-positive and culture-
positive pulmonary TB, and the remainder had smear-nega-
tive but culture-positive TB (Table 1).
Request of AFB
smear/culture
91.5 days (51-170)
75 days (41-149)
43 days (19-77)
26.5 days (9-55)
20 days (*0-71) 28.5 days (14-88)
53 days (25-112) 37 days (*0-89)
67 days (25-124)
80.5 days (28-145)
Initiation of
Anti-TB treatment
Culture Drug susceptibility test (DST)
Report of positive
Mycobacterial culture
Report of 
DST result
Confirmation of AFB culture &
Request for DST
�
Confirmation of 
DST result
Fig. 1. Intervals related to the transmission of the results of drug-susceptibility tests. All numbers in this figure represent days. *When anti-TB
treatment was started after receipt of the result of positive mycobacterial culture, the interval was regarded as 0 days. 
� Drug-susceptibility test.
Male:female 54:50
Median age and range (yr) 41 (17-85)
Diagnosis of tuberculosis
Positive AFB smear and positive mycobacterial culture 46 (44%)
Negative AFB smear but positive mycobacterial culture  58 (56%)
Organ(s) other than lungs that were involved 4 (4%)
Lymph node 1
Brain 1
Knee joint 1
Pericardium 1
Table 1. Demographic characteristics of 104 enrolled patients
with culture-proven pulmonary tuberculosis
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Intervals related to transmission of the results of DST
The median interval between initiation of anti-TB treat-
ment and receipt of reports of positive mycobacterial cultures
by Seoul National University Hospital was 20 days (range,
0-71 days). However, receipt of culture results by clinicians
was delayed (median, 37 days; range, 0-89 days). The median
interval between a request for a DST and receipt of the report
was 28.5 days (range, 14-88 days). From the date of initiation
of anti-TB treatment, 67 days (range, 25-124 days) elapsed
until Seoul National University Hospital received the DST
results, and 80.5 days (range, 28-145 days) elapsed until the
requesting clinicians received them (Fig. 1).
Monthly confirmation of the results of DST after initiation
of the anti-TB treatment
By the end of second month of anti-TB treatment, DST
results for only 16 patients (15%) had been received by clin-
icians. By the third month of treatment, DST results of 57
patients (55%) had been received. The cumulative percent-
ages of DST confirmation at 4, 5, and 6 months were 89%,
99%, and 100%, respectively (Fig. 2). Distribution of patients
according to their intervals of mycobacterial culture and DST
was summarized in Table 2.
DISCUSSION
Current guidelines for treatment of TB published by the
American Thoracic Society/Centers for Disease Control and
Prevention/Infectious Diseases Society of America and the
British Thoracic Society recommend performing DSTs when-
ever possible (5, 6). In addition, these guidelines suggest that
pyrazinamide be discontinued after confirming DST results
excluding drug-resistant TB, although the guidelines of the
Korean Society of Tuberculosis and Respiratory Diseases reco-
mmend that pyrazinamide be discontinued after two months
of the intensive treatment phase regardless of whether DST
results are available or not (8). The long turnaround times
of DSTs conducted using solid media could prolong the two-
month intensive treatment phase (2, 3). However, no reports
have been published on the turnaround times of solid-media
DSTs in clinical settings.
Our study showed that the median interval from initiation
of anti-TB treatment to receipt of DST results by requesting
clinicians was 80.5 days (range, 28-145 days). In addition,
the results of DSTs for which Lowenstein-Jensen media were
used were available to clinicians by the completion of two
months of the intensive phase in only 15% of cases when fol-
low-up was conducted on a monthly basis. This indicates that
the duration of the intensive treatment phase would exceed
two months in 85% of TB patients if pyrazinamide treatment
were discontinued only after DST results were received.
For the treatment of isoniazid-resistant TB, prolongation
of the continuation phase of treatment without pyrazinamide
is recommended if DST results are available later than the
second month of the intensive phase of treatment (5, 6). How-
ever, the development of resistance to rifampicin in a patient
who had isoniazid-resistant TB and had been given prolonged
rifampicin and ethambutol treatment was recently reported
(9, 10). Although prolonged use of pyrazinamide is unnec-
essary for most TB patients, it is best to know the results of
DSTs within two months of initiation of anti-TB treatment.
A shorter DST turnaround time of 28 days could be achieved
by using broth-based systems such as BACTEC (11-13), MB/
BacT (14), ESP (15), or MGIT (16, 17). However, the cost
of broth-based systems is too high for general use, except in
a few developed countries. In addition, DSTs for resistance
to second-line anti-TB drugs still have to be performed using
solid media. 
Considering that a median of 20 days (range, 0-71 days)
elapsed between initiation of treatment and receipt of con-
firmation of a positive mycobacterial culture, and that a medi-
an of 28.5 days (range 14-88 days) elapsed between delivery
Mycobacterial culture Drug susceptibility test
From request to
Report of
result
Confirmation
of result
Report of
result
Confirmation
of result
Median (days) 28 14 28 14
0-10 1 37 0 42
11-20 22 35 1 22
21-30 46 27 53 36
31-40 18 5 31 4
41-50 10 0 10 0
51-60 5 0 4 0
60- 2 0 5 0
Table 2. Distribution of patients according to their intervals of
mycobacterial culture and drug susceptibility test
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Fig. 2. Monthly receipt of the results of drug-susceptibility tests
after initiation of the anti-TB treatment by clinicians *Drug-suscep-
tibility test, 
� Months mean duration of anti-tuberculosis treatment.
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of samples for DSTs and receipt of results, the interval between
initiation of treatment and receipt of DST results might be
reduced by improvement of the process involved in request-
ing or reporting DSTs. 
For example, a system of automatically requesting DST
with mycobacterial colonies from every patient who has not
had a previous DST might reduce the interval to receipt of
DST results, median 14 days in our study. In addition, direct
report of DST results from Korean Institute of Tuberculosis
to the physicians could save another 14.5 days. This direct
reporting system could be easily achieved through e-mail or
mobile phone. However, the interval could not be reduced
to less than eight weeks after initiation of treatment for all
patients because of the wide range of periods required to com-
plete mycobacterial cultures and DSTs using solid media. In
this context, cost-effectiveness of the introduction of liquid
media in Korea, an intermediate TB burden country, should
be analyzed through future studies. In addition, the detection
of resistance using molecular technique could be considered.
In conclusion, clinicians only received the results of DST
more than two months after initiation of treatment when
they followed up patients monthly and the mycobacterial
culture was performed using solid media.
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